DDInter1705 DDInter927
Sparfloxacin is a fluoroquinolone antibiotic indicated for bacterial infections. Sparfloxacin exerts its antibacterial activity by inhibiting DNA gyrase, a bacterial topoisomerase. DNA gyrase is an essential enzyme which controls DNA topology and assists in DNA replication, repair, deactivation, and transcription.
Inotuzumab ozogamicin is an antibody-drug conjugate using linker and cytotoxic drug technology similar to that developed for the ground-breaking treatment Mylotarg (), which was approved by the US FDA in 2000 for the treatment of acute myeloid leukaemia. Inotuzumab ozogamicin consists of a recombinant humanised IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin dimethylhydrazide, which is a potent DNA-binding cytotoxic agent . Developed by Pfizer and UCB, inotuzumab ozogamicin was granted approval by EU in June 2017 followed by FDA on August 17th, 2017 for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). ALL is a rapidly progressing cancer of the bone marrow that is associated with high mortality rates and low therapeutic response from standard chemotherapies in relasping conditions. In a randomized trial, inotuzumab ozogamicin displayed higher percentages of patients undergoing longer periods of complete remission with no evidence of disease in comparison to patients receiving alternative chemotherapy .
Sparfloxacin {u} (Compound) resembles {v} (Compound) Lomefloxacin
Sparfloxacin {u} (Compound) binds {v} (Gene) SLC22A5
Sparfloxacin {u} (Compound) upregulates {v} (Gene) KCTD5
Sparfloxacin {u} (Compound) downregulates {v} (Gene) PKIG
Sparfloxacin {u} (Compound) causes {v} (Side Effect) Atrial flutter
Sparfloxacin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Temozolomide
Sparfloxacin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Paclitaxel
Sparfloxacin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Zinc sulfate
Sparfloxacin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ibuprofen
Sparfloxacin {u} may lead to a major life threatening interaction when taken with {v} Vandetanib
Sparfloxacin (Compound) resembles Lomefloxacin (Compound)
Sparfloxacin (Compound) binds SLC22A5 (Gene)
Sparfloxacin (Compound) upregulates KCTD5 (Gene)
Sparfloxacin (Compound) downregulates PKIG (Gene)
Sparfloxacin (Compound) causes Atrial flutter (Side Effect)
Sparfloxacin may cause a minor interaction that can limit clinical effects when taken with Temozolomide
Sparfloxacin may cause a minor interaction that can limit clinical effects when taken with Paclitaxel
Sparfloxacin may cause a moderate interaction that could exacerbate diseases when taken with Zinc sulfate
Sparfloxacin may cause a moderate interaction that could exacerbate diseases when taken with Ibuprofen
Sparfloxacin may lead to a major life threatening interaction when taken with Vandetanib